Ashton Lavoie

Contact Ashton

Ashton Lavoie

Associate Director, Downstream PD

BridgeBio

Ashton is the Head of Downstream Process Development at BridgeBio Gene Therapy. She has been with BridgeBio for three years, with heavy focus on implementation of strategies and technologies to improve AAV purification processes. She earned her bachelors in Chemical Engineering at Northeastern University, and her masters and Ph.D. in Chemical Engineering at North Carolina State University. She has worked in biomanufacturing for 13 years with academic and industrial experience spanning upstream and downstream process development, technology transfer, and primary cell isolation.

Talks About
#chemical

Preferred Locations
#NorthAmerica

Speaking Engagements

Next Generation CAR & T Cell Therapies 2023

Paid

The exploration of novel cell lines to be used in CAR-based therapies has opened many possibilities for future ‘CGT 2.0’ treatments, both allogeneic and autologous. Join us at our new CAR & T Cell Therapies track within BPI West to learn more about these emerging CGT 2.0 cell lines, and the opportunities they hold.

27 February-02 March 2023

Healthcare

Advances in Purification & Recovery

Paid

Newer and more complex molecules coming down the pipeline are bringing a new set of challenges to the downstream process development team, leading to the search for innovative technologies to meet the demand for higher yield while maintaining product quality and reducing cost. CHI’s Advances in Purification & Recovery conference invites scientists

16-17 August 2023

Healthcare

Claim Your Profile Request

Speaker Contact Request

SPEAKER

Ashton Lavoie

Associate Director, Downstream PD

Speaking Engagements

Next Generation CAR & T Cell Therapies 2023

Advances in Purification & Recovery